Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Launched by UNIVERSITY OF WASHINGTON · Feb 28, 2024

Keywords

ClinConnect Summary

The CHANCES Study is a research trial looking at how certain changes in blood cells, known as clonal hematopoiesis, may affect women who have survived ovarian cancer. The goal is to understand if these changes are linked to a higher risk of developing secondary blood cancers after treatment. Researchers want to explore both genetic factors (inherited traits) and environmental factors (like lifestyle or exposures) that might contribute to this risk.

To participate in this study, women must either currently have or have had ovarian cancer and be receiving or have completed a specific type of treatment called PARPi maintenance therapy. They should also have a good life expectancy of more than six months. Participants can expect to undergo assessments that will help researchers learn more about their health and the potential link to blood cancers. This study is currently recruiting participants, and it aims to provide valuable insights that could improve care for future ovarian cancer survivors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
• • Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
• • OR
• * Subjects who have or have had a solid tumor diagnosis and any of the following:
• • At least 4 months of exposure to a PARP inhibitor
• • Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
• Exclusion Criteria:
• • Individuals with a life expectancy of less than 6 months